Renalytix PLC Director/PDMR share purchase
December 09 2024 - 11:27AM
RNS Regulatory News
RNS Number : 4015P
Renalytix PLC
09 December 2024
Renalytix plc
("Renalytix" or the
"Company")
Director/PDMR share purchase
LONDON and NEW YORK, 9 December 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an
artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to
drive improved patient outcomes and advance value-based
care, announces that today
Howard Doran, President of Renalytix, bought
50,000 ordinary shares of £0.0025 each ("Ordinary Shares") in the
Company at a price of £0.08 per Ordinary Share.
Following this transaction, Howard
Doran is interested in 50,000
Ordinary Shares representing 0.015% of the issued
share capital of the Company.
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com
Notification and public disclosure of
transactions by persons discharging managerial responsibilities and
persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Howard Doran
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
President
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.08
|
50,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
50,000
|
|
- Price
|
£0.08
|
|
|
|
|
e)
|
Date of the transaction
|
9 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUKUBRSVUURAA
Renalytix (LSE:RENX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Dec 2023 to Dec 2024
